Exact Therapeutics AS (OSL:EXTX) ROCE % : -115.64% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Exact Therapeutics AS ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Exact Therapeutics AS's annualized ROCE % for the quarter that ended in Dec. 2023 was -115.64%.

Exact Therapeutics AS ROCE % Historical Data

The historical data trend for Exact Therapeutics AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Therapeutics AS ROCE % Chart

Exact Therapeutics AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-29.82

-32.75

-43.85

-46.66

-86.08

Exact Therapeutics AS Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial						-37.01	-56.29	-39.33	-77.30	-115.64

Exact Therapeutics AS ROCE % Calculation

Exact Therapeutics AS's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-48.297	/	( ( (82.508 - 16.126)	+	(61.319 - 15.486) )	/ 2 )
	=	-48.297	/	( (66.382	+	45.833)	/ 2 )
	=	-48.297	/	56.1075
	=	-86.08 %

Exact Therapeutics AS's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-53.132	/	( ( (52.819 - 6.763)	+	(61.319 - 15.486) )	/ 2 )
	=	-53.132	/	( ( 46.056	+	45.833 )	/ 2 )
	=	-53.132	/	45.9445
	=	-115.64 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Exact Therapeutics AS (OSL:EXTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Exact Therapeutics AS ROCE % Related Terms

Thank you for viewing the detailed overview of Exact Therapeutics AS's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Therapeutics AS (OSL:EXTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exact Therapeutics AS (OSL:EXTX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ostre Aker vei 19, Oslo, NOR, 0581

Website

https://www.exact-tx.com

Exact Therapeutics AS is a clinical-stage biotechnology company. It is developing a technology platform for therapeutic enhancement - Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement that will amplify the clinical utility of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Exact Therapeutics AS (OSL:EXTX) Headlines

No Headlines